Ionis Pharmaceuticals, Inc. (IONS) Q2 FY26 Earnings Call

Commercial launches are tracking to plan, but pipeline catalysts and payer execution remain key determinants of longer-term value.

Q2 FY26 results, source: company transcript and SEC filings
QuarterQ2 FY26
Call date2026-07-29
Length61 minutes
EPS$-0.70
EPS consensus$-1.09
Revenue$267.9M

What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.

Other quarters: Q4 FY25

All IONS earnings ยท Back to IONS overview

Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.